The Use of Intravenous Palivizumab for Treatment of Persistent RSV Infection in Children With Leukemia
Open Access
- 12 November 2012
- journal article
- case report
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 130 (6), e1695-e1699
- https://doi.org/10.1542/peds.2011-1768
Abstract
Palivizumab is a humanized monoclonal antibody used to decrease the threat of respiratory syncytial virus (RSV) infection among children at high risk. There are no standard guidelines due to conflicting data on palivizumab’s use in the treatment of RSV lower respiratory tract infections. Intravenous (IV) palivizumab was shown to be well tolerated and associated with decreased mortality in high-risk children who have RSV disease. However, it did not prevent lower respiratory tract infections and did not affect the survival rate of allogeneic stem cell transplant recipients who had RSV infection. We present 2 children with acute lymphocytic leukemia (ALL) and persistent RSV infection while receiving chemotherapy. Patient A is a 4-year-old male with Down syndrome, ALL, and persistent RSV infection for at least 3 months. Patient B is a 3-year-old female with pre–B cell ALL whose chemotherapy intensification phase was delayed due to a month-long RSV infection. RSV infections were determined by using real-time polymerase chain reaction assays from nasopharyngeal swabs before IV palivizumab therapy; patient A was positive for RSV at 36 cycles and patient B was positive for RSV at 29 cycles. RSV infection was cleared in both patients within 72 hours after receiving IV palivizumab (patient A: 16 mg/kg; patient B: 15 mg/kg). IV palivizumab may be a treatment option for persistent RSV infection among immunocompromised patients.Keywords
This publication has 18 references indexed in Scilit:
- Respiratory syncytial virus prevention and therapy: Past, present, and futurePediatric Pulmonology, 2010
- Increased risk of respiratory tract infections in children with Down syndrome: the consequence of an altered immune systemMicrobes and Infection, 2010
- SAFETY AND ANTIVIRAL ACTIVITY OF MOTAVIZUMAB, A RESPIRATORY SYNCYTIAL VIRUS (RSV)–SPECIFIC HUMANIZED MONOCLONAL ANTIBODY, WHEN ADMINISTERED TO RSV-INFECTED CHILDRENThe Pediatric Infectious Disease Journal, 2009
- Comparison of Viral Isolation and Multiplex Real-Time Reverse Transcription-PCR for Confirmation of Respiratory Syncytial Virus and Influenza Virus Detection by Antigen ImmunoassaysJournal of Clinical Microbiology, 2009
- Respiratory Syncytial Virus Infection in Patients with Hematological Diseases: Single-Center Study and Review of the LiteratureClinical Infectious Diseases, 2008
- Intravenous Palivizumab and Ribavirin Combination for Respiratory Syncytial Virus Disease in High-Risk Pediatric PatientsThe Pediatric Infectious Disease Journal, 2007
- Palivizumab Treatment of Respiratory Syncytial Virus Infection after Allogeneic Hematopoietic Stem Cell TransplantationClinical Infectious Diseases, 2007
- Respiratory Viral Infections in Adults With Hematologic Malignancies and Human Stem Cell Transplantation RecipientsMedicine, 2006
- Immunological features of Down's syndrome: a reviewJournal of Intellectual Disability Research, 1993
- Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice.JCI Insight, 1991